← Leaderboards
Yetrib Hathout
Children'S Research Institute
$3,474,044
Attributed
$5,017,070
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $566.5K · FY2007–24$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,017,070 · 5
By mechanism
R61$1,617,513 · 1
R01$1,468,539 · 1
U54$863,789 · 1
P50$550,028 · 1
R21$517,201 · 1
Top collaborators
- Craig M Mc Donald4 shared
- Utkarsh J Dang3 shared
Most similar at Children'S Research Institute
Same institution · by research overlap
- John Nicolaas Van Den Anker$1,748,539
- Kanneboyina Nagaraju$4,117,501
- Josephine Chen$1,594,227
- Robert Theodore Leshner$12,233
- Hoai Ton$113,750
Others in their field
Top investigators on “Serum”
- Joseph B. Margolick · Johns Hopkins University$72,041,404
- Monica M Bertagnolli · Strang Cancer Prevention Center$59,344,476
- Leonardo Trasande · New York University School Of Medicine$53,176,255
- Bradley F Boeve · Mayo Clinic Rochester$50,650,130
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$50,055,104
- Laurence H Baker · University Of Michigan At Ann Arbor$48,684,161
Research focus
SerumSamplingMuscleOutcome MeasureClinical TrialsCohortLinkDoseDisease ProgressionMonitorMeasurementResponseFutureProteomicsDrug DevelopmentBiological MarkersAdultNatural HistoryBirthPharmaceutical PreparationsCostAdrenal Cortex HormonesDystrophinFunding
Grant awards (15)
Biomarker Signatures for Duchenne Muscular Dystrophy$535,668
R61 · FY2024 · NS · contact PI
Biomarker Signatures for Duchenne Muscular Dystrophy$566,481
R61 · FY2023 · NS · contact PI
Biomarker Signatures for Duchenne Muscular Dystrophy$515,364
R61 · FY2022 · NS · contact PI
Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophy$266,529
P50 · FY2020 · HD · contact PI
Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophy$283,499
P50 · FY2019 · HD · contact PI
Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophy$280,004
U54 · FY2018 · HD · contact PI
Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophy$289,089
U54 · FY2017 · HD · contact PI
Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophy$294,696
U54 · FY2016 · HD · contact PI
Biomarker discovery and validation in a Duchenne dystrophy natural history study$363,901
R01 · FY2014 · AR
Biomarker discovery and validation in a Duchenne dystrophy natural history study$351,346
R01 · FY2013 · AR
Biomarker discovery and validation in a Duchenne dystrophy natural history study$358,863
R01 · FY2012 · AR
Biomarker discovery and validation in a Duchenne dystrophy natural history study$394,429
R01 · FY2011 · AR
Comparative Proteomics to Study Age-Related Maculopathy$64,851
R21 · FY2009 · EY · contact PI
Comparative Proteomics to Study Age-Related Maculopathy$203,350
R21 · FY2008 · EY · contact PI
Comparative Proteomics to Study Age-Related Maculopathy$249,000
R21 · FY2007 · EY · contact PI